Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA

In a akin vein, Argus boosted Vertex’s terms people to $520 connected March 19, highlighting the improved show of its cystic fibrosis brand, particularly triple-combination medicines similar Trikafta/Kaftrio and the expanding Alyftrek regimen.

The ratings travel astir a timeline wherever the United States Food and Drug Administration approved Vertex Pharmaceuticals’ expanded usage of ALYFTREK for treating patients with cystic fibrosis aged 6 and up. The statement hold was backed up by objective and/or successful vitro results from 564 variants responding to ALYFTREK and 521 variants responding to TRIKAFTA.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is simply a planetary biotechnology company. It develops and commercializes therapies for superior diseases, with a superior absorption connected cystic fibrosis and familial disorders.

While we admit the imaginable of VRTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.